Document is current
Any future updates will be listed below
-
Authors
Smolenschi, Cristina
Sisoudiya, Saumya D.
Hollebecque, Antoine
Sivakumar, Smruthy
Montesion, Meagan
Euzen, Victor
Boige, Valérie
Boilève, Alice
Valery, Marine
Sourouille, Isabelle
Bayle, Arnaud
Aldea, Mihaela
Rodriguez, Julieta Elena
Gelli, Massimiliano
Dall’Olio, Filippo Gustavo
Tarabay, Anthony
Pudlarz, Thomas
Bahleda, Rastislav
Fuerea, Alina
Benhaim, Léonor
de Sevilla, Elena Fernandez
Bani, Mohamed
Dartigues, Peggy
Pernot, Simon
Boillet, Gautier
Beshiri, Kristi
Massard, Christophe
Friboulet, Luc
Facchinetti, Francesco
Lacroix, Ludovic
Rouleau, Etienne
Barlesi, Fabrice
Ducreux, Michel
Italiano, Antoine
Sharaf, Radwa
Vasseur, Damien
- License Information
-
More Information
Article History
Received: 15 April 2025
Accepted: 5 November 2025
First Online: 24 November 2025
Competing interests
: C.S.: institutional only: Abbvie, Amgen, Astra-Zeneca, Astellas, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Hoffmann–La Roche Ltd, Genentech, Loxo, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis, and Servier. S.D.S.: is an employee of Foundation Medicine, Inc. and a stockholder of Roche Holding AG. AH: personal fees and nonfinancial support from Amgen, personal fees from Basilea, Bristol Myers and Squibb, Servier, Relay Therapeutics, Taiho, MSD, Seagen, grants and personal fees from Incyte, and nonfinancial support from Pierre Fabre outside the submitted work. S.S.: is an employee of Foundation Medicine, Inc. and a stockholder of Roche Holding AG. M.M.: is an employee of Foundation Medicine, Inc. and a stockholder of Roche Holding AG. V.B.: personal fees from Bayer, Ipsen, Amgen, BMS, MSD, and Roche, and nonfinancial support from AstraZeneca outside the submitted work. M.A.: expenses from Sandoz. L.F.: research funding from Debiopharm, Incyte, Relay Therapeutics, Sanofi, and Nuvalent. F.F.: speaker’s fee from Roche. F.B.: institutional only: Abbvie, ACEA, Amgen, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis, Summit Therapeutics, and Takeda. R.S.: is an employee of Foundation Medicine, Inc. and a stockholder of Roche Holding AG. D.V.: Speaker’s fee from AstraZeneca and Roche. All remaining authors have declared no conflicts of interest.
